Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and Children

Käyhty, Helena; Åhman, Heidi; Rönnberg, Pirjo-Riitta; Tillikainen, Risto; Eskola, Juhani

doi:10.1093/infdis/172.5.1273

Cited by 176 publications

(77 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an arbitrary estimate of protective concentrations of pneumococcal capsular antibodies, we analyzed the cut-off value of 1 µg/ml, as usually done for anticapsular antibodies to Haemophilus influenzae type b (11,12). After vaccination, almost all elderly subjects achieved at least 1 µg/ml of total IgG specific for all six serotypes analyzed.…”

Section: Resultsmentioning

confidence: 99%

Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly

Simonsen

Brandão

Brandileone

et al. 2005

Braz J Med Biol Res

View full text Add to dashboard Cite

Serum antibodies specific for the capsular polysaccharides of Streptococcus pneumoniae provide protection against invasive pneumococcal infection. In Brazil, this vaccine has been used for people over 65 years with clinical risk to develop pneumococcal infection since 1999. We evaluated the immune response of 102 elderly subjects (75.5% females and 24.5% males) with a mean age of 71 years, and 19 young healthy adults (63.2% females and 36.8% males) with a mean age of 27 years. The elderly study group consisted of outpatients who received follow-up care in the Geriatric Department of General Hospital, Faculty of Medicine, University of São Paulo. None had acute illness at the time of vaccination. Both groups were immunized with one intra-deltoid injection with 0.5 ml of a 23-valent pneumococcal polysaccharide vaccine. The total IgG specific antibody concentrations to capsular polysaccharides 1, 3, 5, 6B, 8, and 14 were determined against pre-and 1-month post-vaccination sera. All samples were analyzed according to the second-generation pneumococcal polysaccharide ELISA protocol. We observed that the pneumococcal polysaccharide vaccine evoked consistent antibody increase for serotypes 1, 5, 6B, 8, and 14 (geometric mean concentration increase of 2.46 in the elderly and 2.84 in the young adults). Otherwise, we observed no increase in antibody concentration for serotype 3 in both groups.

show abstract

Section: Resultsmentioning

confidence: 99%

Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly

Simonsen

Brandão

Brandileone

et al. 2005

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…16 The tetanus assay was calibrated in milli-international units (mIU)/ml against the WHO international reference preparation 75/589 (National Institute of Biological Standards and Control (NIBSC), Potters Bar, UK). In the absence of a reference preparation anti-pneumococcal antibodies (APA) were reported in arbitrary ELISA units.…”

Section: Specific Antibody Assays and Definitions Of Serological Respmentioning

confidence: 99%

Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients

Gandhi

Egner

Sizer

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:As a consequence of the significantly larger inoculum of lymphoid cells present in peripheral blood stem cell (PBSC) harvests compared to bone marrow (BM), it is possible that autoPBSCT recipients may have an earlier and/or enhanced response to vaccines. Until data to confirm this become available, the European Blood and Marrow Transplantation Association (EBMT) recommend that all transplant recipients be immunized in the same way regardless of stem cell source. We performed a prospective study comparing serological responses to influenza, pneumococcal polysaccharide and tetanus toxoid vaccines between autoPBSCT with autoBMT recipients. Antibody responses in sibling HLA-matched allogeneic BMT (alloBMT) survivors were also evaluated. All vaccines were administered within the first 2 years after stem cell transplantation. Fifty patients were enrolled. The time of vaccination after transplant was similar between autoPBSCT (mean 11 months for each vaccine) and autoBMT recipients (mean 12 months except 13 months for tetanus toxoid) (P = NS). Serological responses were poor and no significant difference in response to any of the vaccines used was seen between the three transplant cohorts. We provide no evidence that current EBMT guidelines be modified. Large prospective vaccine studies are needed to address the issue more fully. Bone Marrow Transplantation (2001) 28, 775-781.

show abstract

“…The concentrations of IgG antibodies to Pnc PS 19F were measured by enzymeimmunoassay (EIA) described previously by Käyhty et al 24 The results are given as g/ml calculated on the basis of the officially assigned IgG values of the 89-SF reference serum. 25 The lower detection limit for IgG anti-19F was 0.17 g/ml.…”

Section: Eia For Igg Pnc 19f Ps Antibodies and Opsonophagocytic Assaymentioning

confidence: 99%

Opsonophagocytic activity against Streptococcus pneumoniae type 19F in allogeneic BMT recipients before and after vaccination with pneumococcal polysaccharide vaccine

Parkkali

Väkeväinen

Käyhty

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Opsonophagocytic activity (OPA) of pneumococcal polysaccharide (Pnc PS) antibodies in vitro, a measure of antibody functional activity, usually correlates with specific IgG antibody concentrations measured by an EIA method. In order to investigate the functional activity of specific Pnc PS antibodies, we determined IgG antibodies to Pnc PS type 19F by an EIA method and OPA against Pnc type 19F by a killing assay in a randomized study, where 23 adult allogeneic BMT recipients were vaccinated with Pnc PS vaccine at 8 months (early group) and 21 recipients at 20 months (late group) after transplantation. Serum samples drawn before BMT, before vaccination, and at 1 and 16 months after vaccination were available from 27, 35, 34 and 30 patients, respectively. The geometric mean antiPnc 19F concentrations were 4.3, 1.3, 1.6 and 1.3 g/ml in the early group and 3.8, 0.9, 0.6 and 0.6 g/ml in the late group before transplantation, before vaccination, and at 1 and 16 months after vaccination, respectively. OPA (titre у8) was found in 10/27, 5/35, 5/34 and 6/30 patients before BMT, before vaccination, and at 1 and 16 months after vaccination, respectively. The specific IgG antibody concentration and OPA correlated with each other before BMT, and in the early group patients before and at 1 month after vaccination. The results demonstrate that after Pnc PS vaccination allogeneic BMT recipients have antibodies with low functional activity to a Pnc PS antigen associated with low specific IgG responses. There is a need to study new Pnc conjugate vaccines in multi-dose schedules for their capacity to elicit higher specific antibody concentrations with high OPA in BMT recipients. Bone Marrow Transplantation (2001) 27, 207-211. Keywords: opsonophagocytic activity; BMT recipients; pneumococcal antibodies Streptococcus pneumoniae (Pnc) is the main cause of bacterial infections in allogeneic BMT recipients surviving Ͼ3

show abstract

Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and Children

Cited by 176 publications

References 27 publications

Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly

Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly

Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients

Opsonophagocytic activity against Streptococcus pneumoniae type 19F in allogeneic BMT recipients before and after vaccination with pneumococcal polysaccharide vaccine

Contact Info

Product

Resources

About